Clinical Trials : Mantle Cell Lymphoma

Completed

Nombre del estudio: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Condición: Mantle Cell Lymphoma
Fecha: 2026-01-10
Intervenciones: Given by PO

COMPLETED

Nombre del estudio: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Condición: Mantle Cell Lymphoma
Fecha: 2026-01-10
Intervenciones: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for do

COMPLETED

Nombre del estudio: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
Condición: Mantle Cell Lymphoma
Fecha: 2026-01-10
Intervenciones: Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food,

COMPLETED

Nombre del estudio: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial
Condición: Recurrent Mantle Cell Lymphoma
Fecha: 2026-01-10
Intervenciones: Undergo blood, saliva or tissue sample collection

COMPLETED

Nombre del estudio: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Condición: Mantle Cell Lymphoma
Fecha: 2026-01-10
Intervenciones: Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3

COMPLETED

Nombre del estudio: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Condición: Relapsed/Refractory Mantle Cell Lymphoma
Fecha: 2026-01-10
Intervenciones: Administered intravenously

COMPLETED

Nombre del estudio: The Role of 18F-FDG-PET for Staging and Prognostication
Condición: Mantle Cell Lymphoma
Fecha: 2026-01-10

Buscar resultados de ensayos clínicos

Mantle Cell Lymphoma - 27 Studies Found

Estado	Estudiar
Completed	Nombre del estudio: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients Condición: Mantle Cell Lymphoma Fecha: 2026-01-10 Intervenciones: Given by PO
COMPLETED	Nombre del estudio: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2026-01-10 Intervenciones: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for do
COMPLETED	Nombre del estudio: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2026-01-10 Intervenciones: Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food,
COMPLETED	Nombre del estudio: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial Condición: Recurrent Mantle Cell Lymphoma Fecha: 2026-01-10 Intervenciones: Undergo blood, saliva or tissue sample collection
COMPLETED	Nombre del estudio: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2026-01-10 Intervenciones: Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
COMPLETED	Nombre del estudio: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) Condición: Relapsed/Refractory Mantle Cell Lymphoma Fecha: 2026-01-10 Intervenciones: Administered intravenously
COMPLETED	Nombre del estudio: The Role of 18F-FDG-PET for Staging and Prognostication Condición: Mantle Cell Lymphoma Fecha: 2026-01-10